MedTrace Logo

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19

NCT05047718 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2024-12-11

No results posted yet for this study

Summary

Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population. However, immunosenescence appears to play a role in the natural post-COVID-19 immunity of convalescent elderly subjects and also in the post-vaccination response. However, vaccination recommendations for both naïve (2 doses of vaccine) and convalescent subjects (1 dose of vaccine) do not differ according to age. To date, there is little data to suggest that the response to the vaccine in naïve or convalescent subjects may vary according to age in terms of qualitative and quantitative response and duration.

Conditions

  • Covid19

Interventions

BIOLOGICAL

COVID-19 vaccine Pfizer (3 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 vaccine Pfizer (2 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (3 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (2 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (1 dose)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    collaborator INDUSTRY

  • Bioster, a.s.

    collaborator INDUSTRY

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Elisabeth BOTELHO-NEVERS, MD PhD · CHU de St Etienne

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2022-08-29
Completion
2023-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047718 on ClinicalTrials.gov